Connection

David Mahvi to Dose-Response Relationship, Immunologic

Back to Details
This is a "connection" page, showing publications David Mahvi has written about Dose-Response Relationship, Immunologic.
David Mahvi
Connection Strength
0.015
Dose-Response Relationship, Immunologic
  1. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006 Jul; 55(7):761-74.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.